sulfadoxine-pyrimethamine + azithromycin

A combination of the antimalarial agents sulfadoxine and pyrimethamine with the macrolide antibiotic azithromycin. Sulfadoxine and pyrimethamine act synergistically to inhibit folate synthesis in Plasmodium species by targeting dihydropteroate synthase (sulfadoxine) and dihydrofolate reductase (pyrimethamine), thereby blocking parasite DNA synthesis. Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit; it also exhibits antimalarial activity through inhibition of apicoplast protein synthesis in Plasmodium parasites. This combination has been investigated primarily for intermittent preventive treatment in pregnancy (IPTp) against malaria, aiming to reduce maternal parasitemia, improve birth outcomes, and provide additional antibacterial benefits[1][4][5]. The regimen is particularly relevant where resistance to standard IPTp regimens is increasing.

Other names

sulfadoxine-pyrimethamine and azithromycinSP + AZIAZI-SP